Scholars Central

Conference abstractPublished 17 Sep 2018

Compatibility studies of rivaroxaban, a novel oral anticoagulant drug, with excipients in film-coated tablets

Authors: Kian Navaee, Fatemeh Soltani

Shahre Daru Pharmaceutical Co, Iran

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pharmaceutical dosage form is a combination of active pharmaceutical ingredients (APIs) and excipients. Excipients are included in dosage forms to aid manufacture, administration or absorption. Studies of drug-excipient compatibility represent an important phase in the preformulation stage of the development of all dosage forms. In summary, knowledge of drug-excipient interactions is a necessary prerequisite to the development of dosage forms that are stable and of good quality. Drug-excipient compatibility studies have been used as an approach for accepting/rejecting excipients for use in pharmaceutical formulations, thus allowing the rapid optimization of a dosage form with respect to patentability, processing, drug release, elegance and physicochemical stability. To assess the drug-excipients compatibility, the analytical techniques like Differential Scanning Calorimetry (DSC) and Fourier Transform Infrared Spectroscopy (FT-IR) and High performance liquid chromatography (HPLC) were adopted. In the present study, the possible interactions between rivaroxaban, a novel oral anticoagulant drug, and some excipients (povidone, lactose monohydrate, sodium lauryl sulfate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate and film coating materials) were evaluated by examining the pure drug or drugexcipient powder mixtures which were stored under different conditions (40 ± 2ºC, RH 75 ± 5%) and different period (30, 90 and 180 days) using DSC, FT-IR and HPLC. No concrete evidence of interaction was observed between drug and the excipients. On the basis of the results obtained from DSC, FT-IR and HPLC studies, all the excipients used were found to be compatible with the drug and can be used for the development of formulation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical Care & Health Systems.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical Care & Health Systems
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Kian Navaee”
  • BylineArticles whose byline prints “Fatemeh Soltani”